Clinical Trials Directory

Trials / Completed

CompletedNCT01297920

Three Month Efficacy/Safety Study With a 3-Month Safety Extension of Brinzolamide 1%/Brimonidine 0.2% vs. Brinzolamide 1% or Brimonidine 0.2%

A Three-Month, Randomized, Double-Masked, Parallel-Group Study With a Planned Three-Month Safety Extension of the Efficacy and Safety of a Fixed Combination of Brinzolamide 1%/Brimonidine 0.2% Compared to Brinzolamide 1% and Brimonidine 0.2% All Dosed Three Times Daily in Patients With Open-Angle Glaucoma and/or Ocular Hypertension

Status
Completed
Phase
Phase 3
Study type
Interventional
Enrollment
1,062 (actual)
Sponsor
Alcon Research · Industry
Sex
All
Age
18 Years
Healthy volunteers
Not accepted

Summary

The purpose of this study was to evaluate the safety and efficacy of a new ophthalmic suspension (Brinz/Brim) in lowering intraocular pressure (IOP) relative to its individual active components in subjects with open-angle glaucoma and/or ocular hypertension.

Detailed description

This study consisted of 7 visits conducted during 2 sequential phases: the screening/eligibility phase, which included a screening visit and 2 eligibility visits, and the treatment phase, which included 4 on-therapy visits conducted at Week 2, Week 6, Month 3, and Month 6. A washout period based on previous ocular medication preceded Eligibility Visit 1. Subjects who met all inclusion/exclusion criteria at both eligibility visits were randomized to 1 of 3 study drug groups. The study was designed to evaluate the efficacy and safety of Brinzolamide/Brimonidine over a 3-month period, with an additional 3 months of study drug exposure intended to provide further safety data.

Conditions

Interventions

TypeNameDescription
DRUGBrinzolamide 1%/brimonidine tartrate 0.2% ophthalmic suspension
DRUGBrinzolamide ophthalmic suspension, 1%
DRUGBrimonidine tartrate ophthalmic solution, 0.2%

Timeline

Start date
2011-03-01
Primary completion
2012-06-01
Completion
2012-06-01
First posted
2011-02-17
Last updated
2013-07-04
Results posted
2013-07-04

Source: ClinicalTrials.gov record NCT01297920. Inclusion in this directory is not an endorsement.